ESR1 and neoplasm: ESR1 mutations that mutate its ligand binding domain constitute one of the most important driving mechanisms of endocrine resistance [3, 4, 6], whereas the growth of the xenograft tumor models ectopically expressing ESR1 mutations can be effectively inhibited by endocrine treatment [40].